Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Geriatr Psychiatry Neurol ; 25(1): 29-36, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22467844

ABSTRACT

INTRODUCTION: In recent years, concerns about the use of antipsychotic medications in dementia have grown. There is limited data on mortality risk of atypical antipsychotics for other psychiatric disorders of later life such as bipolar disorder. METHODS: Data were derived from the national Department of Veterans Affairs registries for older patients with bipolar disorder (≥65 years) with a new start of an atypical antipsychotic (risperidone, olanzapine, or quetiapine) or valproic acid and derivatives during fiscal years 2001-2008. Six-month mortality rates were compared for individual drug groups. RESULTS: The sample included 4717 patients. The risperidone cohort had the highest mortality rate (11.8 per 100 person-years) with the quetiapine and valproic acid cohorts having the lowest (5.3 and 4.6 per 100 person-years, respectively). Various methods to adjust for baseline differences including propensity models showed similar patterns. CONCLUSIONS: Among older patients with bipolar disorder, there may be differences in mortality risks among individual antipsychotic agents.


Subject(s)
Antipsychotic Agents/adverse effects , Bipolar Disorder/drug therapy , Age Factors , Aged , Aged, 80 and over , Antipsychotic Agents/therapeutic use , Benzodiazepines/adverse effects , Benzodiazepines/therapeutic use , Bipolar Disorder/mortality , Dibenzothiazepines/adverse effects , Dibenzothiazepines/therapeutic use , Female , Humans , Kaplan-Meier Estimate , Male , Olanzapine , Proportional Hazards Models , Quetiapine Fumarate , Risk Factors , Risperidone/adverse effects , Risperidone/therapeutic use , Valproic Acid/adverse effects , Valproic Acid/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL